As of 2025-11-18, the Relative Valuation of NextCell Pharma AB (NXTCL.ST) is (9.40) SEK. This relative valuation is based on P/E multiples. With the latest stock price at 0.79 SEK, the upside of NextCell Pharma AB based on Relative Valuation is -1284.1%.
The range of the Relative Valuation is (10.25) - (8.71) SEK.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 32.5x - 33.5x | 33.0x |
| Forward P/E multiples | 25.6x - 27.6x | 26.6x |
| Fair Price | (10.25) - (8.71) | (9.40) |
| Upside | -1391.4% - -1196.7% | -1284.1% |
| Date | P/E |
| 2025-11-14 | -2.52 |
| 2025-11-13 | -2.53 |
| 2025-11-12 | -2.36 |
| 2025-11-11 | -2.44 |
| 2025-11-10 | -2.57 |
| 2025-11-07 | -2.60 |
| 2025-11-06 | -2.69 |
| 2025-11-05 | -2.67 |
| 2025-11-04 | -2.73 |
| 2025-11-03 | -2.82 |
| 2025-10-31 | -2.87 |
| 2025-10-30 | -2.84 |
| 2025-10-29 | -2.82 |
| 2025-10-28 | -2.83 |
| 2025-10-27 | -2.78 |
| 2025-10-24 | -2.94 |
| 2025-10-23 | -2.94 |
| 2025-10-22 | -3.00 |
| 2025-10-21 | -2.94 |
| 2025-10-20 | -2.90 |
| 2025-10-17 | -2.92 |
| 2025-10-16 | -2.81 |
| 2025-10-15 | -2.85 |
| 2025-10-14 | -2.87 |
| 2025-10-13 | -2.92 |
| 2025-10-10 | -2.94 |
| 2025-10-09 | -2.98 |
| 2025-10-08 | -3.00 |
| 2025-10-07 | -2.97 |
| 2025-10-06 | -3.01 |
| 2025-10-03 | -3.09 |
| 2025-10-02 | -3.09 |
| 2025-10-01 | -3.06 |
| 2025-09-30 | -3.01 |
| 2025-09-29 | -2.95 |
| 2025-09-26 | -3.06 |
| 2025-09-25 | -3.07 |
| 2025-09-24 | -3.14 |
| 2025-09-23 | -3.13 |
| 2025-09-22 | -3.19 |
| 2025-09-19 | -3.16 |
| 2025-09-18 | -3.21 |
| 2025-09-17 | -3.25 |
| 2025-09-16 | -3.22 |
| 2025-09-15 | -3.34 |
| 2025-09-12 | -3.40 |
| 2025-09-11 | -3.26 |
| 2025-09-10 | -3.28 |
| 2025-09-09 | -3.44 |
| 2025-09-08 | -3.52 |